Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution [0.03%]
靶向髓系肿瘤中凋亡功能障碍——治疗革命的前景
Enrico Santinelli,Maria Rosaria Pascale,Zhuoer Xie et al.
Enrico Santinelli et al.
In recent years, the therapeutic landscape of myeloid malignancies has been completely revolutionized by the introduction of several new drugs, targeting molecular alterations or pathways crucial for leukemia cells survival. Particularly, m...
Prashant Kapoor,S Vincent Rajkumar
Prashant Kapoor
Waldenström macroglobulinemia (WM) is a unique CD20+, B-cell non-Hodgkin lymphoma, characterized by lymphoplasmacytic infiltration of the bone marrow and circulating monoclonal immunoglobulin M. The clinical manifestations and outcomes of ...
Noffar Bar,Ross S Firestone,Saad Z Usmani
Noffar Bar
Frontline therapy for multiple myeloma (MM) is evolving to include novel combinations that can achieve unprecedented deep response rates. Several treatment strategies exist, varying in induction regimen composition, use of transplant and or...
Factor XI inhibitors for the prevention of cardiovascular disease: A new therapeutic approach on the horizon? [0.03%]
因子XI抑制剂在心血管疾病预防中的应用：一个新的治疗策略吗？
D Santagata,M P Donadini,W Ageno
D Santagata
Anticoagulant drugs that are currently used to prevent and/or treat thrombosis have some limitations that hinder their ability to meet specific clinical requirements. While these drugs effectively reduce the rates of thrombotic events, they...
Marika Bini Antunes,Sara Pinto Cardeal,Manuel Magalhães et al.
Marika Bini Antunes et al.
Recent developments of assisted reproduction techniques turned possible to avoid the infertility consequences of oncologic treatments, but fertility preservation (FP) has been somewhat neglected in women with hematologic diseases undergoing...
Awareness of individual goals, preferences, and priorities of persons with severe congenital haemophilia A for a tailored shared decision-making approach to liver-directed gene therapy. A practical guideline [0.03%]
了解严重先天性甲型血友病患者个体目标、偏好和优先级的意识，以制定个性化的共同决策方法进行肝脏定向基因治疗。实用指南
Giovanni Di Minno,Gaia Spadarella,Nelson Mauro Maldonato et al.
Giovanni Di Minno et al.
In clinical medicine, shared decision making (SDM) is a well-recognized strategy to enhance engagement of both patients and clinicians in medical decisions. The success of liver-directed gene therapy (GT) to transform severe congenital haem...
The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment [0.03%]
核心结合因子急性髓系白血病的核心概念：当前预后和治疗的考虑因素
Christina Darwish,Kyle Farina,Douglas Tremblay
Christina Darwish
Core binding factor acute myeloid leukemia (CBF AML), defined by t(8;21) or inv(16), is a subset of favorable risk AML. Despite its association with a high complete remission rate after induction and relatively good prognosis overall compar...
Do anemia treatments improve quality of life and physical function in patients with myelodysplastic syndromes (MDS)? A systematic review [0.03%]
一项系统性回顾：改善骨髓增生异常综合征患者生活质量和身体机能的贫血治疗措施的效果如何？
Allison Mo,Matthew Poynton,Erica Wood et al.
Allison Mo et al.
Anemia is common in Myelodysplastic Syndromes (MDS). Different anemia treatments have been tested in clinical studies, but the full impact on patients' health-related quality of life (HRQoL) and physical function is unknown. The main aim of...
Yevgen Chornenkyy,Takayuki Yamamoto,Hidetaka Hara et al.
Yevgen Chornenkyy et al.
Transfusion of allogeneic human red blood cell (hRBCs) is limited by supply and compatibility between individual donors and recipients. In situations where the blood supply is constrained or when no compatible RBCs are available, patients s...
Primary and secondary immune thrombocytopenia (ITP): Time for a rethink [0.03%]
原发和继发免疫性血小板减少症(ITP)，是时候重新思考了
Tomás José González-López,Drew Provan,Abelardo Bárez et al.
Tomás José González-López et al.
There are not many publications that provide a holistic view of the management of primary and secondary ITP as a whole, reflecting the similarities and differences between the two. Given the lack of major clinical trials, we believe that co...